Akebia Therapeutics Inc

AKBANASDAQ · USD
0.45USD-0.02 (-4.10%)
612

Akebia Therapeutics Inc (AKBA) Covered Calls

Akebia Therapeutics Inc trades in the Drug Manufacturers - Specialty & Generic industry with an IV Rank of 72.62%, high versus the past year. AKBA's highest covered call setup is the $5.00 strike expiring Jan 21, 2028, sorted by theoretical annualized return. It's 963.83% out of the money with 434 days to expiration, a 974.47% return until expiration, and a 819.54% theoretical annualized return. Across the setups shown, annualized returns run from 41.16% to 819.54% at strikes between $0.50 and $5.00, with 154 to 434 days to expiration, as of Nov 13, 2026.

Read more

Running AKBA covered calls helps you generate income from Akebia Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AKBA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If AKBA stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AKBA covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AKBA covered call is worth writing.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.

2028-01-214345.00963.830.050.10458.00974.47819.54-10.64+0.291,0090.05
2028-01-214342.50431.910.050.15208.00442.55372.19-10.64+0.391,3950.10
2028-01-214342.00325.530.050.15158.00336.17282.72-10.64+0.401,6850.10
2028-01-214341.50219.150.050.15108.00229.79193.25-10.64+0.418800.10
2027-04-161540.506.380.100.3513.0027.6665.56-21.28+0.736310.25
2028-01-214340.506.380.200.2523.0048.9441.16-42.55+0.741,4010.05

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV Rank72.62% High
  • Market cap (M$)132
  • 52 weeks high-74.46%
  • 52 weeks low30.56%
  • Analyst recommendationStrong Buy
    1.33
  • Target price$3.00
    614.60% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-0.16
  • EPS growth next 5 years—

As of Nov 13, 2026